PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 21 June 2023, 07:00 am CEST Data presented at EASL Congress 2023 alfapump was effective in the control of ascites, virtually eliminating needle paracentesis Safety in line with expectations – particularly given disease progression in these patients – six primary safety events and limited number of key secondary...Read More
SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 15.78 MILLION IN AN EQUITY PLACEMENT Ghent, Belgium, 25 April 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it successfully raised an amount of EUR 15.78 million...Read More
Ghent, Belgium, 24 April 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today the launch of an equity offering to raise an amount of approximately EUR 15 million by means of a private placement...Read More
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 15 November 2022, 07:00 am CET Data from SAHARA with first-generation DSR product (DSR 1.0) confirm: Safe, effective and rapid elimination of persistent congestion following intensive DSR therapy Considerable benefit in cardio-renal status maintained till end of study (16 weeks post-intensive DSR therapy) Dramatic and sustained improvement...Read More
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 25 October 2022, 07:00 am CET alfapump achieves pre-specified primary effectiveness endpoints with statistical significance at six months post-implantation: 100% median per-patient reduction in therapeutic paracentesis (TP) post- vs pre-implantation (p<0.001) 77% of patients with at least 50% reduction in number of TP post- vs pre-implantation (p<0.001)...Read More
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 8 September 2022, 07:00 CET alfapump® – strong interim data / on track to report primary endpoint data of North American pivotal POSEIDON study in Q4 2022 DSR® – clinical evidence of disease-modifying heart failure drug therapy / preparations ongoing to start US phase 1b/2a MOJAVE study...Read More
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 20 July 2022, 07:00 CET Company’s cash runway extended into Q3 2023 Ghent, Belgium – 20 July 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces...Read More
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 19 July 2022, 07:00 am CEsT DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart...Read More
Ghent, Belgium, 8 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces today that it successfully raised an amount of EUR 28.4 million in gross proceeds by means of a private placement...Read More
Ghent, Belgium, 7 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces today the launch of an equity offering to raise an amount of approximately up to EUR 28 million by means...Read More
